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Abstract
Bis(dichlorophosphino)methane was converted to a β,γ-methylenetriphosphitylating reagent. The
reagent was immobilized on aminomethyl polystyrene resin-bound linker of 4-acetoxy-3-
phenylbenzyl alcohol to afford a polymer-bound β,γ-methylenetriphosphitylating reagent, which was
reacted with unprotected nucleosides followed by oxidation with tert-butyl hydroperoxide,
deprotection of cyanoethoxy groups with DBU, and acidic cleavage, to produce 5′-O-β,γ-methylene
triphosphate nucleosides in 53-82% overall yields. Among all the compounds, cytidine 5′-O-β,γ-
methylenetriphosphate inhibited completely RNase H activity of HIV-1 reverse transcriptase at 700
μM.
Phosphate transfer is involved in several enzymatic catalyzed reactions1-3 and therefore is a
subject of considerable interest in biological systems. Triphosphate mimics, such as
methylenetriphosphates, halogenated methylenetriphosphates, and imidotriphosphates, have
been used to probe the mechanism of phosphoryl transfer in enzyme-catalyzed processes2-4
and to target specific receptors or enzymes that bind or hydrolyze triphosphates.5-8
Replacement of labile P-O-P bond in nucleoside triphosphates with a stable isosteric P-CH2-
P bond in nucleotide analogs results in enhanced metabolic stability. Synthesis of non-
hydrolyzable triphosphate analogs of nucleosides is considered a challenge.
A number of solution phase strategies have been previously reported for the synthesis of
nucleoside 5′-O-β,γ-methylenetriphosphates including some of the compounds described here
by the coupling reactions of nucleoside 5′-monophosphate salt forms or activated nucleoside
monophosphates with diphosphonates (methylene diphosphonic acids). Some examples
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include the reactions of methylene diphosphonic acids with nucleoside 5′-monophosphates,9,
10 5′-monophosphate-N-methylimidazolides,11,12 or 5′-monophosphate-imidazolides13.
Alternatively, sequential Michael-Arbuzov reactions on ethyl(bishalomethyl) phosphinates8
were used for the synthesis of the bismethylene triphosphates. These synthetic strategies
analogs have been encountered by one or more of the following difficulties. (i) Activated
nucleoside monophosphates or their specific salt forms are required for the synthesis of 5′-O-
β,γ-methylenetriphosphate nucleoside analogs, respectively. (ii) The coupling reactions are
mostly carried out in anhydrous organic solvents. Because of the poor solubility of most
precursor phosphates in the reaction mixture, the yields are usually low. (iii) Stepwise lengthy
purification of intermediates and final products from the reagents are required. (iv) These
strategies require protection and deprotection reactions for most of nucleosides. Thus,
alternative convenient strategies for the preparation of 5′-O-β,γ-methylenenucleoside
triphosphates are highly desired.
Herein, we report for the first time a solid-phase strategy for the synthesis of β,γ-
methylenetriphosphate nucleoside analogs by using a novel solid-supported phosphitylating
reagent. A β,γ-methylenetriphosphitylating reagent was prepared first. Aminomethyl
polystyrene resin-bound linker of p-acetoxybenzyl alcohol14 was used as solid support for
immobilization of β,γ-methylenetriphosphitylating reagent. The unprotected nucleosides were
reacted with the immobilized reagent. Subsequent oxidation, deprotection, and cleavage
afforded the β,γ-methylenetriphosphate nucleoside analogs.
Scheme 1 illustrates the synthesis of β,γ-methylenetriphosphitylating reagent 6. Phosphorus
trichloride (1, 6 mmol) was reacted with diisopropylamine (2 equiv) to yield bis
[diisopropylamino]phosphorochloridite (2). The subsequent reaction of 2 with water (1 equiv)
afforded the intermediate bis[diisopropylamino]hydroxyphosphine (3).
In a separate reaction, bis(dichlorophosphino)methane 4 (6 mmol) was treated with 3-
hydroxypropionitrile (3 equiv) to yield 5, which was reacted with 3 (1 equiv) to yield β,γ-
methylenetriphosphitylating reagent (6). The chemical structure of 6 was confirmed by high-
resolution time-of-flight electrospray mass spectrometry (ESI-TOF) and elemental phosphorus
analysis. Compound 6 was immediately used for the next coupling reaction with polymer-
bound p-acetoxybenzyl alcohol 7 to avoid any decomposition.
Aminomethyl polystyrene resin-bound linker of p-acetoxybenzyl alcohol (7) was synthesized
from aminomethyl polystyrene resin in multiple-step reactions14 and was selected as a solid
support for immobilization of the β,γ-methylenetriphosphitylating reagent. We have previously
reported the application of the p-acetoxybenzyl alcohol linkers for the solid-phase synthesis
of diverse number of compounds, such as carbohydrate and nucleoside monophosphates,
15-17 diphosphates, diphosphodithioates, triphosphates, or triphosphotrithioates,18 nucleoside
β-triphosphates,19 oligodeoxynucleotides containing internucleotide diphosphodiester
linkages,20 sulfonamides,14 symmetrical 5′,5′-dinucleoside mono-, di-, tri-, and
tetraphosphodiesters,21 and nucleoside 5′-O-α,β-methylene-β-triphosphates22.
Scheme 2 shows the synthesis of nucleoside α,β- and β,γ-methylenetriphosphates. Polymer-
bound linker 7 was reacted with β,γ-methylenetriphosphitylating reagent (6, 1.2 equiv) in the
presence of 5-(ethylthio)-1H-tetrazole to produce the corresponding polymer-bound β,γ-
methylenetriphosphitylating reagent 8. The treatment of unprotected nucleosides (4 mmol, e.g.,
adenosine (a), 3′-azido-3′-deoxythymidine (b), thymidine (c), cytidine (d), and inosine (e))
with 8 (1 mmol) in the presence of 5-(ethylthio)-1H-tetrazole gave 9a–e, respectively.
Oxidation with tert-butyl hydroperoxide followed by removal of the cyanoethoxy group with
DBU, afforded the corresponding polymer-bound nucleoside β,γ-methylenetriphosphates,
11a–e. Subsequent steps were supported by FT-IR peaks for all the intermediate resins. The
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cleavage of polymer-bound compounds was carried out under mild acidic conditions, DCM/
TFA/water/EDT (72.5:23:2.5:2 v/v/v/v). The crude products had a purity of 67-92% and were
purified on the C18 Sep-Pak cartridges to afford nucleoside β,γ-methylenetriphosphates, 14a–
e (Scheme 2) in 53-82% overall yield (calculated from 8) (Table 1) (269-411 mg). The purity
of compounds were calculated based on the weight of pure and crude compounds.
Among all the synthesized methylenetriphosphate derivatives, 14d is a novel compound.
Adenosine, cytidine, and inosine contain a secondary (2′ and/or 3′) alcohol, a primary (5′)
alcohol, or a free amino group. Only 5′-O-substituted compounds were purified with high
selectivity as a result of this sequence. The presence of the phosphitylating reagents on the
solid support having a hindered structure allowed for the regioselective reaction of the
unprotected nucleosides with the polymer-bound phosphitylating reagents. There was no need
to protect the free aromatic amino group in adenosine and cytidine. The most reactive hydroxyl
group of unprotected nucleosides reacted selectively with hindered and bulky polymer-bound
reagents when an excess of nucleoside was used. The compounds were characterized by 1H
NMR, 13C NMR, 31P NMR, ESI-TOF, and phosphorus elemental analysis.
Nucleoside methylenetriphosphates remain attractive probes and nonhydrolyzable
triphosphate mimics in studying and inhibiting the phosphate transfer in biological systems.
The synthesized compounds were evaluated to determine whether they can inhibit human
immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), a critical enzyme in HIV
life cycle.
HIV-1 RT converts the single-stranded RNA genome into double-stranded DNA that is later
integrated into the host genome.23 Retroviral RT's are multifunctional enzymes possessing
DNA polymerase activities on both DNA and RNA templates, as well as a ribonuclease H
(RNase H) activity that hydrolyzes the RNA of RNA/DNA replication intermediates. HIV-1
RT is a heterodimer consisting of p66 and p51 subunits that share the same sequence at the N-
terminus. The RNase H domain resides in the C-terminus of p66 subunit, which is not present
in p51.24 Both DNA polymerase and RNase H activities of HIV-1 RT have been considered
as potential targets for antiretroviral therapy. However, all currently used HIV-1 RT inhibitors
are directed against the polymerase function of the enzyme.25 Designing compounds that block
the RNase H activity of the HIV-1 RT have been challenging. Although recent screening efforts
led to the discovery of few RNase H inhibitors, none of them advanced into clinical trials.
RNase H has been a challenging target for a number of reasons. Inhibitors that block the RT-
associated RNase H function have higher cytotoxicity, since they interfere with the functions
of cellular counterparts. RNase H proteins, including human RNase H, are homologous and
share a similar three-dimensional fold. To address these challenges and to discovery of potent
RNase H inhibitors we examined the potency of synthesized modified nucleoside analogs
against RNase H and polymerase function of HIV-1 RT.
Initially we evaluated the potency of the compounds with modified phosphates towards the
RNase H activity of HIV-1 RT at a fixed concentration (1 mM) of the compounds. RNase H
assay was performed using recombinant RT and RNA/DNA hybrids as previously
described26-28. The results of the RNase H cleavage are presented in Figure 1A. Lane W
represents the RNase H cleavage products in the absence of any inhibitor. Lanes a-e represent
the RNase H cleavage products in the presence of the compounds 14a–e, respectively. These
results indicate that the RNase H activity of HIV-1 RT is inhibited by the cytidine derivative
14d (lane 4). Therefore, we tested the potency of compound 14d by performing concentration
dependent inhibition assays. RNase H inhibition was not observed up to 100 μM with the
compound. The results from 100 μM-1 mM are presented in Figure 1B. Compound 14d
achieved complete inhibition of the RNase H activity at 700 μM (Figure 1B, lane 6). These
results are consistent with our earlier studies that showed another modified nucleoside
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triphosphate derivative, cytidine 5′-O-α,β-methylene-β-triphosphate inhibited RNase H
activity of HIV-1 reverse transcriptase.22
We have also tested the potency of these compounds against the polymerase function of HIV-1
RT (Figure 2). In comparison to the wild type enzyme (lane w), the polymerase activity was
not affected in the presence of the compound 14 a–e, (lanes a-e). However, compound 14c
caused the polymerase complex to pause several positions during DNA synthesis (lane c). Since
compound 14d did not inhibit the polymerase activity of HIV-1 RT (lane 4), it can provide
insights for designing of additional compounds, which may have better inhibitory activity
against the RNase H activity.
To the best of our knowledge, this is the first report of the synthesis of nucleoside β,γ-
methylenetriphosphates by using solid-phase reagents without the need for precursors, such as
nucleoside monophosphates or 5′-methylenediphosphonate analogs. Unreacted reagents were
removed by extensive washing of the resins in each step. This solid-phase strategy offered the
advantages of expeditious synthesis, 5′-O-substitution, high selectivity, facile isolation and
purification of final products.
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Figure 1.
A. RNase H analysis of HIV-1 RT in the presence of compounds 14 a–e. Lane w represents
no inhibitor. The RNase H cleavage of HIV-1 RT was inhibited by 14d; B. RNase H activity
with increased concentration of compounds 14d. Lane 1 (100 μM), lane 2 (200 μM), lane 3
(300 μM), lane 4 (400 μM), lane 5 (500 μM), lane 6 (700 μM), and lane 7 (1 mM). The
unhydrolyzed substrate is marked as U, whereas the cleavage products are marked as C.
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Figure 2.
DNA polymerase activity of HIV-1 RT in the presence of compounds 14a–e (1 mM). Lane w
represents no inhibitor. The radiolabeled primer is marked as P, whereas the fully extended
product is marked as P+18.
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Scheme 1.
Synthesis of β,γ-methylenetriphosphitylating reagent 6.
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Scheme 2.
Synthesis of nucleoside 5′-O-β,γ-methylenetriphosphates 14a–e using polymer-bound reagent
8.
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Table 1
Overall isolated yields and purity of crude products for 14a–e.
No. Overall yield (%) calcd from 8 Purity of crude products
14a 75 87
14b 81 92
14c 82 90
14d 57 78
14e 53 67
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